Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PDE6D | O43924 | 3/20 | 0.33 |
| ▸ | PDE6A | P16499 | 3/20 | 0.33 |
| ▸ | PDE6G | P18545 | 3/20 | 0.33 |
| ▸ | PDE6B | P35913 | 3/20 | 0.33 |
| ▸ | PDE6C | P51160 | 3/20 | 0.33 |
| ▸ | PDE6H | Q13956 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23830424 | 0.84 | TSHR (0.39) | TSHRKDM1AFFAR2 | |
| SCHEMBL23830411 | 0.81 | HSD17B10 (0.43) | HSD17B10KDM4EPDE6DPDE6APDE6G | |
| SCHEMBL23830360 | 0.81 | HSD17B10 (0.45) | TSHRHSD17B10KDM4EPDE6DPDE6A | |
| SCHEMBL25467307 | 0.79 | TSHR (0.47) | TSHRKDM1AFFAR2 | |
| SCHEMBL23830402 | 0.75 | ACACB (0.45) | HSD17B10PDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16395481 | 0.74 | HSD17B10 (0.35) | HSD17B10PDE6DPDE6APDE6GPDE6B | |
| SCHEMBL23830372 | 0.71 | HSD17B10 (0.45) | TSHRHSD17B10HTTKDM4E | |
| SCHEMBL22143386 | 0.69 | TSHR (0.41) | TSHRKDM1AFFAR2 | |
| SCHEMBL25517393 | 0.68 | TSHR (0.44) | TSHRHTTKDM1AFFAR2 | |
| SCHEMBL12236490 | 0.67 | CHRM1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | US | disclosed |
| CN-112543757-A | Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus | 卡迪拉保健有限公司 | 2021-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | DPEP1, SAT1, PEPD | TSHR 2466/4885HSD17B10 1210/4885HTT 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.